Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
Ayalew Tefferi, J. Thiele, Alessandro M. Vannucchi, et al.
Leukemia (2014) Vol. 28, Iss. 7, pp. 1407-1413
Open Access | Times Cited: 214

Showing 1-25 of 214 citing articles:

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, et al.
Blood (2016) Vol. 127, Iss. 20, pp. 2391-2405
Open Access | Times Cited: 9112
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, et al.
Leukemia (2018) Vol. 32, Iss. 5, pp. 1057-1069
Open Access | Times Cited: 491
Myeloproliferative Neoplasms
Ayalew Tefferi, Animesh Pardanani
JAMA Oncology (2015) Vol. 1, Iss. 1, pp. 97-97
Closed Access | Times Cited: 295
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
Ayalew Tefferi, Paola Guglielmelli, Terra L. Lasho, et al.
Leukemia (2014) Vol. 28, Iss. 7, pp. 1494-1500
Open Access | Times Cited: 271
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2015) Vol. 90, Iss. 2, pp. 162-173
Closed Access | Times Cited: 242
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
Sonia Cerquozzi, Ayalew Tefferi
Blood Cancer Journal (2015) Vol. 5, Iss. 11, pp. e366-e366
Open Access | Times Cited: 221
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi, Tiziano Barbui
American Journal of Hematology (2016) Vol. 92, Iss. 1, pp. 94-108
Open Access | Times Cited: 215
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Sa A. Wang, Robert P. Hasserjian, Patricia S. Fox, et al.
Blood (2014) Vol. 123, Iss. 17, pp. 2645-2651
Open Access | Times Cited: 201
Targeted deep sequencing in primary myelofibrosis
Ayalew Tefferi, Terra L. Lasho, Christy Finke, et al.
Blood Advances (2016) Vol. 1, Iss. 2, pp. 105-111
Open Access | Times Cited: 201
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
Ayalew Tefferi, Emnet A Wassie, Paola Guglielmelli, et al.
American Journal of Hematology (2014) Vol. 89, Iss. 8
Closed Access | Times Cited: 197
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12
Samer A. Srour, Susan S. Devesa, Lindsay M. Morton, et al.
British Journal of Haematology (2016) Vol. 174, Iss. 3, pp. 382-396
Open Access | Times Cited: 173
Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification
Jürgen Thiele, H. M. Kvasnicka, Umberto Gianelli, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
Xénia Cabagnols, Fabrizia Favale, Florence Pasquier, et al.
Blood (2015) Vol. 127, Iss. 3, pp. 333-342
Open Access | Times Cited: 174
Myeloproliferative neoplasms: A decade of discoveries and treatment advances
Ayalew Tefferi
American Journal of Hematology (2015) Vol. 91, Iss. 1, pp. 50-58
Open Access | Times Cited: 164
Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi
American Journal of Hematology (2016) Vol. 91, Iss. 12, pp. 1262-1271
Open Access | Times Cited: 148
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations
Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, et al.
Blood (2015) Vol. 126, Iss. 24, pp. 2585-2591
Open Access | Times Cited: 145
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Alessandro M. Vannucchi, Tiziano Barbui, Francisco Cervantes, et al.
Annals of Oncology (2015) Vol. 26, pp. v85-v99
Open Access | Times Cited: 124
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
Tiziano Barbui, J. Thiele, Alessandro M. Vannucchi, et al.
Blood Cancer Journal (2015) Vol. 5, Iss. 8, pp. e337-e337
Open Access | Times Cited: 117
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances
Tiziano Barbui, J. Thiele, Heinz Gisslinger, et al.
Blood Reviews (2016) Vol. 30, Iss. 6, pp. 453-459
Closed Access | Times Cited: 110
Primary myelofibrosis: 2014 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi
American Journal of Hematology (2014) Vol. 89, Iss. 9, pp. 915-925
Closed Access | Times Cited: 107
Pathogenesis of myeloproliferative neoplasms
Radek C. Skoda, Adrian Duek, Jean Grisouard
Experimental Hematology (2015) Vol. 43, Iss. 8, pp. 599-608
Open Access | Times Cited: 106
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
Tariq I. Mughal, Nicholas C.P. Cross, E. Padron, et al.
Haematologica (2015) Vol. 100, Iss. 9, pp. 1117-1130
Open Access | Times Cited: 98
How I treat polycythemia vera
Alessandro M. Vannucchi
Blood (2014) Vol. 124, Iss. 22, pp. 3212-3220
Open Access | Times Cited: 87
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
A.M. Vannucchi, Giada Rotunno, Niccolò Bartalucci, et al.
Leukemia (2014) Vol. 28, Iss. 9, pp. 1811-1818
Open Access | Times Cited: 85
The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms
Mads Emil Bjørn, Hans Carl Hasselbalch
Mediators of Inflammation (2015) Vol. 2015, Iss. 1
Open Access | Times Cited: 79
Page 1 - Next Page

Scroll to top